FATE THERAPEUTICS INC (FATE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$36.4M
Cash & Equivalents
$30.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$361M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-31 | Phase2 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06922890 | First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cor... | PHASE2 | Recruiting | 9 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.